The second round of the European Union’s Innovative Medicines Initiative (IMI2) that starts in the New Year has been designed to ease funding applications by interested companies and other organisations forming consortia to develop innovative drugs, according to Michel Goldman, IMI Executive Director.
‘We have to continue to simplify the reporting,’ Goldman told Manufacturing Chemist, referring to the financial and narrative reporting requested from grant beneficiaries when they receive European public money.
He also wants to continue increasing the number of opportunities for SMEs to apply for R&D funding through the programme. ‘When we started [2008], we launched one call a year; now we are launching calls for proposals as soon as the topic is ready – last year we had four calls for proposals,’ Goldman said. These topics are developed by a consortium of member companies of the European Federation of Pharmaceutical Industries and Associations (EFPIA).
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.